Freenome Stock

freenome.comHealthcare / BioTech & PharmaFounded: 2014Funding to Date: $1.1B

Freenome is a biotechnology company driven to provide the tools needed to detect, treat and prevent cancer using routing blood draw. This company was founded in 2014 by Gabe Otte, Riley Ennis, Charles Roberts and is headquartered in South San Francisco, CA. Freenome combines molecular biology with advanced computational biology and machine learning to help with early cancer detection.

Register To Buy and Sell Shares

For more details on financing and valuation for Freenome, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in


Enterprise Value

Powered by Forge Data

Access Freenome’s valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Freenome.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.


Animation displayed is not current and securities are shown for illustrative purposes only.


Management Team

Charles Roberts
Co-Founder & Chief Growth Officer
Mike Nolan
Chief Executive Officer
Riley Ennis
Chief Product Officer
Jimmy Lin
Chief Scientific Officer
Julie Tran
Chief People Officer
Lance Baldo
Chief Medical Officer
Michael Ash
Chief Commercial Officer
Charles Roberts
Chief Growth Officer

Board Members

Douglas Robertson, MD
White River Junction Veterans Affairs Medical Center
Daniel F Hayes, MD
University of Michigan
William Grady, MD
Fred Hutchinson Cancer Research Center
Alberto Gutierrez, PhD
NDA Partners
Sherie Smalley, MD

Frequently Asked Questions About Freenome’s Stock

Can you buy Freenome stock?
Freenome is not publicly traded on NYSE or NASDAQ in the U.S. To buy Freenome stock you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.
Can you sell Freenome stock?
Yes, you can sell stock of a private company like Freenome. Forge can help you sell your Freenome stock in a way that works for you and the company. So if you are seeking liquidity, register with us today to get started.
What is Freenome’s stock price?
Freenome is a privately held company and therefore does not have a public stock price. However, you may access Freenome’s private market stock price with Forge Data.
What is Freenome’s stock ticker symbol?
Freenome does not have an official ticker symbol because this company is not currently publicly traded.
Can institutional investors buy and sell private market stocks?
Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

News Highlights

Walgreens and Freenome Partner to Increase Diversity in Research Focused on the Early Detection of Cancer
Walgreens and biotech firm Freenome have announced a multi-year partnership to advance clinical studies of Freenome's blood-based tests for early cancer detection. Walgreens will use its national footprint and patient insights to engage diverse patient populations in Freenome's multi-cancer research program. The partnership will also work on building risk-prediction models and population health software to help identify people eligible for standard-of-care cancer detection testing.
University becomes Freenome's study partner for multi-cancer screening approach
The Institute for Population and Precision Health (IPPH) at the University of Chicago has partnered with biotech company Freenome for a study aimed at refining Freenome's multiomics platform for multi-cancer screening. The study, named Vallania, will use machine learning to detect cancer at early stages using a standard blood draw. This partnership is a significant step in Freenome's plan to expand early cancer detection beyond colorectal cancer.
Freenome Adds Renown Health as Partner for the Sanderson Study
Freenome, a biotech company, has partnered with Renown Health for the Sanderson Study, which uses real-world data and multiomics for the detection of multiple cancers. The study aims to generate evidence of clinical validation for certain high-risk populations and refine the platform's cancer classification and risk prediction models. The Sanderson Study will enroll approximately 8,000 patients across the US.
Updated on: Dec 2, 2023


Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.